Respiratory Distress Syndrome 2016 Landscape Report for Global API Manufacturers on Marketed and Phase III Drugs

01 Feb, 2016, 07:30 ET from ReportsnReports

PUNE, India, February 1, 2016 /PRNewswire/ --

ReportsnReports.com adds "Respiratory Distress Syndrome - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" and "Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2015" with 2018 Forecasts to its online business intelligence library.

Market research report titled Respiratory Distress Syndrome - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Respiratory Distress Syndrome Report is to understand the market and pipeline status of the drugs around the Respiratory Distress Syndrome to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Respiratory Distress Syndrome. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India. Complete report on Distress Syndrome with 14 tables and 12 figures, spread across 100 pages is available at http://www.reportsnreports.com/reports/455274-respiratory-distress-syndrome-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2016.html .

Scope of this report : A snapshot of the global Market and Phase III therapeutics scenario for Respiratory Distress Syndrome, A review of the marketed products under prescription for Respiratory Distress Syndrome, regulatory information and marketing status, Coverage of global patent coverage and detailed commentaries on the US patent challenges, Graphical representation of investigational products for patent expiry and market exclusivities across the globe, Product profiles for marketed products for Respiratory Distress Syndrome with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details, Coverage of API Manufacturers for Respiratory Distress Syndrome drugs in the United States, Europe and Asian Regions with location details, Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Respiratory Distress Syndrome drugs,  Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Respiratory Distress Syndrome drugs, Coverage of Respiratory Distress Syndrome Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress, Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs, Key discontinued Marketed products, Global Sales Figure to 2018. Order a copy of Respiratory Distress Syndrome - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 report at http://www.reportsnreports.com/purchase.aspx?name=455274 .

Another research titled Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2015 provides an overview of Respiratory Distress Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Respiratory Distress Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Companies discussed in this report include Ikaria Holdings, Inc., GlaxoSmithKline Plc, Serendex Pharmaceuticals A/S, Pierrel S.p.A., Forest Laboratories, Inc. (Inactive), F. Hoffmann-La Roche Ltd., Abbott Laboratories, Actelion Ltd, National Heart, Lung, and Blood Institute etc. Read more at http://www.reportsnreports.com/reports/413387-respiratory-distress-syndrome-global-clinical-trials-review-h2-2015.html .

Explore more pharmaceuticals market reports at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com


SOURCE ReportsnReports